YY1-Binding lncRNA Library Preparation for Cancer Therapeutics

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods lack effective means to modulate RNA-YY1 interactions, which are crucial for regulating gene expression, particularly in the context of long non-coding RNAs and their role in transcriptional control and cancer treatment.

Innovation Solution

Development of methods to prepare libraries of nuclear ribonucleic acids (nRNAs) that specifically bind YY1, including contacting nRNAs with YY1 protein and a binding agent, isolating complexes, and synthesizing complementary DNA (cDNA) to identify and select for sequences that are enriched or have high read counts, enabling the modulation of gene expression and identification of therapeutic targets for cancer.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Adaptability or versatility

If methods are developed to prepare libraries of nRNAs that specifically bind YY1, then the ability to modulate gene expression is improved, but the complexity of the experimental procedure increases

Engineering Contradiction:

Improveability to modulate gene expressionVSAvoidcomplexity of experimental procedure

Core Design Contradiction:

Adaptability or versatilityVSDevice complexity

Solution Approach 1:

The complex experimental procedure is divided into distinct modular steps: (a) contacting nRNAs with YY1 protein and binding agent to form complexes, (b) isolating the complexes, (c) synthesizing cDNA complementary to nRNAs, and (d) selecting enriched cDNAs. Each step can be independently optimized and performed, reducing overall procedural complexity while maintaining the ability to modulate gene expression.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

A YY1 binding agent is introduced as an intermediary component to facilitate the specific binding of nRNAs to YY1 protein. This binding agent acts as a mediator that enables the formation of stable nRNA-YY1 complexes, which can then be isolated and analyzed. The intermediary binding agent simplifies the overall process by providing a reliable method to capture and enrich specific RNA-protein interactions.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If compounds are identified that disrupt YY1 binding with long non-coding RNAs, then therapeutic potential for cancer treatment is improved, but the time and resources required for compound screening increase

Engineering Contradiction:

Improvetherapeutic potential for cancer treatmentVSAvoidtime and resources for compound screening

Core Design Contradiction:

ReliabilityVSLoss of time

Solution Approach 1:

The library of nRNAs that specifically bind YY1 is prepared and characterized in advance, creating a pre-validated target set for compound screening. This preliminary preparation includes isolating YY1-nRNA complexes, synthesizing cDNAs, and identifying enriched sequences. By having this library ready beforehand, subsequent compound screening can proceed more efficiently with known high-confidence targets, reducing the time and resources needed for discovery.

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The method incorporates enrichment analysis and RPKM threshold filtering to identify high-confidence nRNA-YY1 interactions. This feedback mechanism allows researchers to focus compound screening efforts on the most relevant RNA targets, thereby reducing the search space and accelerating the identification of therapeutic compounds that disrupt YY1 binding.

Inventive Principle:

Principle #23Feedback

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

These methods allow for the modulation of gene expression by disrupting YY1 binding with long non-coding RNAs, providing potential therapeutic targets for cancer treatment by identifying differentially expressed RNAs and compounds that inhibit tumor cell proliferation or induce cell death.

Implementation Method 1

contacting the sample with an agent, e.g., an antibody, that binds specifically to YY1 protein, under conditions sufficient to form complexes between the agent and YY1 proteins

Methodology Applied

Scientific EffectAntibody-antigen binding: